Opinion
Accepted on 13 Nov 2025
Iron reduction via periodic calibrated phlebotomy to target ferritin lowers cancer incidence and mortality in patients with peripheral artery disease: further insights from the FeAST trial
in Cancer Epidemiology and Prevention